查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1858230

α1-抗胰蛋白酶缺乏症治疗市场按治疗方法、通路、给药方式、最终用户和患者年龄组划分 - 全球预测（2025-2032 年）

Alpha 1 Antitrypsin Deficiency Treatment Market by Therapy Class, Distribution Channel, Delivery Mode, End User, Patient Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，α-1 抗胰蛋白酶缺乏症治疗市场将成长至 67.9 亿美元，复合年增长率为 9.62%。

关键市场统计数据
基准年 2024 32.6亿美元
预计年份：2025年 35.7亿美元
预测年份 2032 67.9亿美元
复合年增长率 (%) 9.62%

本书清晰而有力地概述了α1-抗胰蛋白酶缺乏症治疗模式演变过程中的科学进展和患者就医挑战。

α1-抗胰蛋白酶缺乏症是一种具有重要临床意义的遗传性疾病，会显着影响肺功能和肝功能等。这促使治疗格局不断发展，将成熟的生物製药与新一代基因疗法结合。过去十年，临床实践主要依赖替代疗法和血浆衍生疗法来稳定以肺部受累为主的患者病情，而转化研究的蓬勃发展则推动了基因疗法进入临床应用。因此，研发、生产和医疗服务等各环节的相关人员正在重新调整工作重点，以平衡长期临床预期与短期可近性挑战。

如本执行摘要所述，该领域的特点是治疗方式和给药模式的多样性。虽然传统的增强疗法和血浆输注仍然是许多患者的核心治疗选择，但以腺结合病毒和慢病毒载体为特色的基因疗法平台正在发展成为潜在的根治性方案。通路正从医院药房转向线上和零售管道，给药方式也日益多样化，包括吸入和静脉注射，这些都在重塑着患者获得治疗的方式。患者群体的多样性，包括成人、老年患者和儿童，进一步增加了临床路径和报销方式的复杂性。综上所述，这些趋势要求在研究、供应链和商业性执行方面製定协调一致的策略，以将科学进步转化为实际的患者获益。

科学进步、剂量创新和分销管道的改变如何重塑 AATD 治疗的临床开发和商业性进程

α1-抗胰蛋白酶缺乏症的治疗格局正因科学、监管和商业性的重大转折点而发生变革，这些转折点共同重新定义了研发重点。载体生物学和基因编辑平台的突破性进展正在加速转化研究，并增加探索基于腺相关病毒（AAV）和慢病毒载体疗法的早期临床试验的频率。同时，载体生产、纯化和衣壳工程技术的进步正在缩小实验室可行性与可扩展临床供应之间的差距，这正在影响关键性临床试验计画的规划。

同时，给药方式的创新正在重塑临床设计和病患体验。吸入给药策略因其直接肺部给药以控制肺部疾病而日益受到重视，而静脉注射途径则在全身暴露和基因递送方面不断优化。通路也在不断调整，医院药房在复杂输液和特殊操作中仍然发挥着核心作用，而线上药房和零售药房则在拓展业务，以支持维持治疗和慢性病护理的物流。这些技术和物流方面的变革与支付方的期望和监管路径相互交织，促使研发人员投入资源，以产生可靠的真实世界证据并监测长期安全性。因此，生物技术创新者、合约开发组织和专业医疗保健网路之间的合作对于快速将候选药物从研究阶段推进到临床实践至关重要。

2025年美国关税政策变化对生物製药供应链、采购趋势和病患取得途径的策略影响

贸易和关税政策的变化对医药和生物製药生态系统产生了实际且迅速的影响。美国于2025年宣布的关税措施的累积影响，将需要供应链、采购和定价管道进行策略性调整。影响进口原料和生产组件的关税可能会增加血浆衍生产品和生物载体生产的直接生产成本，这些产品通常需要从国外购买专用试剂和设备。这些成本压力可能会波及契约製造关係，迫使各方重新谈判供应条款，并将生产规模策略性地重新分配到国内工厂。

除了直接的成本影响外，关税还会降低库存灵活性，延长关键材料的前置作业时间，从而增加供应链计划的复杂性，并提高依赖稳定血浆供应或按时生产载体的专案的营运风险。医院药局和专科诊所的采购团队可能会面临利润压力，这可能导致采购模式的改变和合约结构的重新评估。为此，发起机构可以透过加快关键生产流程的本地化、寻求长期供应协议或寻找合格的替代供应商来降低风险。重点，监管方面的考虑和支付方的谈判将影响增量成本最终如何在支付方、医疗服务提供方和患者之间分配，因此，包括证据收集和定价模型在内的跨职能缓解策略对于确保患者获得治疗至关重要。

深入的市场细分洞察，解释了治疗层级、通路、给药方式、最终使用环境和患者人口统计特征如何决定策略重点和营运权衡。

对α1-抗胰蛋白酶缺乏症治疗领域的細項分析突显了相关人员必须关注的不同商业性和临床载体，以优化开发和应用。就治疗层级而言，替代疗法和血浆输注仍然是许多患者目前治疗的基础，营运重点在于血浆采集网路、低温运输物流和输注基础设施。基因治疗具有独特的风险回报特征。在此类别中，腺相关病毒（AAV）载体方法因其靶向肝臟和肺部的体内基因递送优势而备受青睐，而慢病毒载体策略通常用于体外造血模型或特定的全身递送靶点。每种载体类型都涉及独特的生产、免疫抗原性和监管方面的考量，这些因素会影响临床试验设计和长期安全性监测。

通路的变化趋势对患者的用药可及性和依从性有显着影响。虽然医院药局在复杂、高度规范的疗法和基因疗法的初始给药方面仍然至关重要，但线上药局正逐渐成为慢性病护理和宅配计画的便捷途径。零售药局提供社区层面的用药服务，并通常支持维持治疗的连续性。给药方式的选择进一步加剧了患者体验的差异：吸入疗法能够实现标靶肺部沉积，并为门诊患者带来更多便利；而静脉注射则有助于在临床环境中实现全身暴露和剂量控制。最终使用者的差异也十分重要：居家照护模式允许病患在医疗机构外进行慢性输注；医院是急诊和复杂手术的中心；而专科诊所则集中了基因治疗给药和长期监测方面的专业知识。最后，患者年龄层的差异也造成了临床差异，影响治疗方案的选择、给药策略和安全性监测。儿科患者需要儿科专用製剂和发展阶段相适应的安全性数据，而成人通常是最大的治疗族群。老年患者面临合併症和多重用药等问题，这些问题会影响药物的耐受性和治疗效果。

区域间法规环境、临床基础设施和供应链能力的差异将如何影响全球市场的发展路径和病患获取途径

区域趋势将对α1-抗胰蛋白酶缺乏症计画的临床开发、报销策略和供应链韧性产生重大影响。在美洲，重点研究活动、完善的临床试验基础设施和成熟的血浆采集系统共同为先进疗法的开发创造了有利环境。监管途径仍然是核心考虑因素，监管机构要求提供可靠的安全性数据和长期追踪数据，以确定试验终点和核准后义务。该地区的商业相关人员还必须应对支付方的期望和复杂的医院采购流程，以确保治疗方法的广泛应用。

欧洲、中东和非洲地区（EMEA）的监管和准入环境复杂多样，既有集中式框架，也有国家层面的框架。虽然一些欧洲市场提供强有力的孤儿药诱因和加速审批机制，但报销标准和卫生技术评估要求的差异可能导致各国在药物可近性方面有显着差异。在中东和非洲部分地区，血浆基础设施有限且缺乏专业的医疗网络，使得先进疗法的引入更加复杂，凸显了进行有针对性能力建设工作的重要性。

亚太地区的特点是临床研究活动快速扩张、本地生产能力不断提升，以及监管协调日益加强，旨在缩短临床开发週期。该地区多个国家正在投资生物製造和载体生产能力，这有望支持区域供应多元化。然而，病患可及性和定价趋势因市场而异，因此需要製定反映当地支付体系、分销生态系统和医疗实践模式的复杂商业化策略。在所有地区，管理跨境供应链、海关风险和物流应急措施对于确保产品供应稳定和患者照护的连续性仍然至关重要。

深入了解产业相关人员之间的策略联盟、製造投资和实证项目如何加速临床应用和商业化进程。

企业和生态系统层面的努力正在影响创新型AATD治疗方法从概念到临床，最终走向常规实践的进程。包括小型生物技术创新者、成熟的血浆疗法公司、合约研发生产机构和专科药房网络在内的多元化参与者，在药物发现、载体生产和患者支持方面提供互补的能力。随着研发人员寻求将科学专长与大规模生产能力和成熟的分销网络相结合，战略合作和许可授权变得越来越普遍。

为了因应基因治疗和血浆衍生产品营运的复杂性，商业机构正优先投资于载体生产、低温运输物流和病患支援服务的产能。能够证明其生产产量稳定且品质系统符合规范的契约製造製造商，是寻求降低关键专案风险的申办方的策略伙伴。同时，专科药房和家庭输液服务提供者正在加强其临床支援和监测项目，以优化患者的依从性和安全性。在商业层面，各公司也致力于制定循证策略，使临床结果与支付方的要求相符，强调真实世界疗效、生活品质指标和长期安全性数据，以推动医保覆盖和报销方面的讨论。总而言之，这些企业层面的选择凸显了整合式、跨职能模式的转变，这种模式将卓越的临床水准与商业性现实相结合。

为赞助商和合作伙伴提供切实可行的优先策略步骤，以加强供应链、产生证据并实现以患者为中心的AATD疗法的商业化。

为了驾驭复杂且快速发展的抗胰蛋白酶缺乏症（AATD）生态系统，产业领导者应优先考虑一系列切实可行的策略，以平衡短期营运韧性和长期创新。首先，透过对多家地理位置分散的供应商进行资格认证，并在条件允许的情况下投资国内生产能力，实现血浆衍生材料和载体生产供应链的多元化，从而降低关税和物流风险。其次，将可靠的真实世界资料收集和病患报告结果纳入试验设计和核准后註册研究，以加速产生能够消除支付方顾虑并加强报销谈判的临床证据。

第三，透过开发适当的给药途径和製剂，例如院内启动、居家持续治疗或门诊吸入维持治疗，使产品开发与供应和分销实际情况相符。第四，与契约製造、专科药房和临床研究中心建立跨学科合作，以确保生产的扩充性和高品质的患者支援。第五，积极与监管机构和卫生技术评估机构合作，确定可接受的终点指标和风险管理计划，尤其针对新型基因疗法。最后，投资于以患者为中心的项目，以减少依从性障碍并支持长期监测，尤其是在儿童和老年人群中，因为这些人群的安全性和耐受性考虑因素有所不同。透过协作实施这些建议，各机构可以维持药物的可及性，最大限度地减少营运中断，并增强新型治疗方法的临床提案。

本执行摘要清楚地描述了一种混合调查方法，该方法结合了初步访谈、文献综合和供应商营运评估，以得出可靠的实用结论。

本执行摘要的研究整合了多种调查方法，对α1-抗胰蛋白酶缺乏症的治疗现状进行了严谨而实用的分析。主要研究包括对临床研究人员、专科药剂师、生产经理和支付方代表进行结构化访谈，以收集有关临床实践、营运限制和医保覆盖范围等方面的第一手观点。次要研究包括对同行评审文献、临床试验註册库、监管指导文件和上市公司披露资讯进行全面审查，以梳理科学进展、临床试验活动和监管预期。

供应链和製造方面的洞察来自供应商评估和公开的产能报告，而分销管道分析则纳入了药房服务产品和居家照护项目模式的数据。在适当情况下，我们检验验证了主要和次要来源，以检验趋势并识别相互矛盾的讯号。透过跨职能审查和品质保证检查，我们保持了分析的征兆，确保结论反映出一致的证据。此调查方法的局限性包括临床计画推广时间表的不确定性以及政策环境变化所带来的不确定性。为了缓解这些局限性，我们强调风险调整后的情境和营运应对措施，而非精确的数值预测。

具有前瞻性的综合愿景，强调在研发、生产和支付方参与等环节开展协作策略，以将科学进步转化为病患持续的用药途径。

生物製药、基因创新和不断演进的分销模式的融合，标誌着α1-抗胰蛋白酶缺乏症治疗的关键转折点。科学进步正在创造实际的机会，使我们从症状治疗转向更永续的治疗方案，但要实现这一目标，需要製定一套涵盖临床开发、生产韧性和医保支付方参与的综合策略。透过将载体平台选择与给药方式相匹配，并将可靠的真实世界证据纳入监管和报销讨论，相关人员可以减少推广应用的障碍，并改善患者的治疗效果。

展望未来，研发人员、契约製造、专科医疗机构和支付方之间的合作对于将科学进步转化为广泛的患者获益至关重要。营运准备情况，尤其是在供应链多元化和定价策略方面，将决定哪些治疗方法能够实现永续的可及性。最终，以患者为中心，优先考虑安全性、长期监测和公平可及性的方法，不仅能够推进临床治疗，还能为该治疗领域的创新治疗方法开闢永续的商业性道路。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 利用CRISPR技术进行新兴基因编辑疗法，在肺部达到α1-抗胰蛋白酶的持续表达
  • 吸入式重组AAT製剂的临床进展，旨在提高患者依从性和治疗效果
  • 整合远端医疗平台，用于即时监测和个人化管理AAT缺乏症
  • 透过扩大新生儿筛检计划，促进α1-抗胰蛋白酶缺乏症的早期诊断和治疗
  • 在欧洲法规环境变化与价格压力下，生物相似药AAT产品打入市场策略
  • 一种创新的基于奈米颗粒的递送系统，可增强α-1抗胰蛋白酶疗法的肺部标靶化
  • 长效AAT製剂的引入可减少输血频率并提高慢性治疗的依从性
  • 扩大患者登记合作，以产生真实世界证据，支持对AAT疗法进行健康技术评估。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依治疗方法的α1-抗胰蛋白酶缺乏症治疗市场

  • 替代疗法
  • 基因治疗
    • AAV载体
    • 慢病毒载体
  • 血浆输注

9. 依分销管道分類的α1-抗胰蛋白酶缺乏症治疗市场

  • 医院药房
  • 网路药房
  • 零售药房

10. 依给药方式分類的α1-抗胰蛋白酶缺乏症治疗市场

  • 吸入
  • 静脉注射

第十一章 以最终用户分類的α1-抗胰蛋白酶缺乏症治疗市场

  • 居家医疗
  • 医院
  • 专科诊所

12. 依患者年龄层分類的α1-抗胰蛋白酶缺乏症治疗市场

  • 成人
  • 老年人
  • 孩子们

13. 各地区α1-抗胰蛋白酶缺乏症治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 α1-抗胰蛋白酶缺乏症治疗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国α1-抗胰蛋白酶缺乏症治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Grifols SA
    • CSL Behring GmbH
    • Takeda Pharmaceutical Company Limited
    • Kamada Pharmaceuticals
    • Vertex Pharmaceuticals
Product Code: MRR-C002B1C99847

The Alpha 1 Antitrypsin Deficiency Treatment Market is projected to grow by USD 6.79 billion at a CAGR of 9.62% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.26 billion
Estimated Year [2025] USD 3.57 billion
Forecast Year [2032] USD 6.79 billion
CAGR (%) 9.62%

A clear and compelling overview of the evolving therapeutic paradigm for alpha-1 antitrypsin deficiency that frames scientific advances and patient access challenges

Alpha-1 antitrypsin deficiency remains a clinically significant, genetically driven disorder that disproportionately affects pulmonary and hepatic function, prompting an evolving therapeutic landscape that blends established biologics with next-generation genetic interventions. Over the past decade, clinical practice has relied on augmentation approaches and plasma-derived therapies to stabilize patients with lung-dominant disease, while a surge of translational research has propelled gene-based strategies toward the clinic. Consequently, stakeholders across development, manufacturing, and care delivery are recalibrating priorities to reconcile long-term clinical promise with near-term access challenges.

As this executive summary outlines, the field is characterized by a diversified set of therapeutic modalities and delivery paradigms. Traditional augmentation therapy and plasma infusion remain core treatment options for many patients, while gene therapy platforms-distinguished by adeno-associated viral vectors and lentiviral vectors-are advancing as potentially curative alternatives. Parallel shifts in distribution-from hospital pharmacies to online and retail channels-and delivery modes such as inhalation and intravenous administration are reshaping how therapies reach patients. Patient age heterogeneity, including adult, geriatric, and pediatric populations, further complicates clinical pathways and reimbursement approaches. Taken together, these dynamics demand coordinated strategy across research, supply chain, and commercial execution to translate scientific advances into tangible patient benefit.

How converging scientific advances, delivery innovations, and distribution shifts are reshaping clinical development and commercial execution for AATD therapies

The treatment landscape for alpha-1 antitrypsin deficiency is undergoing transformative shifts driven by scientific, regulatory, and commercial inflection points that collectively redefine development priorities. Breakthroughs in vector biology and gene-editing platforms have accelerated translational activity, increasing the frequency of early-phase studies that explore both AAV vector-based and lentiviral vector-based approaches. At the same time, improvements in vector manufacturing, purification, and capsid engineering are narrowing the gap between laboratory promise and scalable clinical supply, which in turn influences sponsor planning for pivotal programs.

Concurrently, delivery-mode innovation is reshaping clinical design and patient experience. Inhalation strategies aimed at direct pulmonary delivery are gaining traction for lung-centric disease control, while intravenous routes continue to be optimized for systemic exposure and gene delivery. Distribution channels are adapting as well, with hospital pharmacy settings retaining a central role for complex infusions and specialty procedures, while online and retail pharmacies scale to support maintenance therapies and chronic care logistics. These technical and logistical changes intersect with payer expectations and regulatory pathways, prompting developers to invest in robust real-world evidence generation and long-term safety monitoring. As a result, partnerships between biotech innovators, contract development organizations, and specialty care networks are becoming essential for moving candidates from bench to bedside at pace.

Strategic implications of recent United States tariff policy changes on biologics supply chains, procurement dynamics, and patient access pathways in 2025

Policy changes in trade and tariff regimes have real and rapidly materializing implications for the pharmaceutical and biologics ecosystem, and the cumulative impact of United States tariffs announced in 2025 warrants strategic attention across supply chain, procurement, and pricing channels. Tariffs affecting imported raw materials and manufacturing components can increase direct production costs for plasma-derived products and biologic vector manufacturing, which rely on specialized reagents and equipment often sourced internationally. These cost pressures ripple through contract manufacturing relationships and may necessitate renegotiation of supplier terms or strategic reallocation of manufacturing volumes to domestic facilities.

Beyond direct cost effects, tariffs can introduce complexity into supply chain planning by reducing inventory flexibility and increasing lead times for critical inputs, thereby heightening operational risk for programs reliant on steady plasma supplies or on-time vector production. Procurement teams within hospital pharmacies and specialty clinics may experience tighter margins, potentially prompting shifts in purchasing patterns or contract structures. In response, sponsorship organizations may accelerate localization of key manufacturing steps, pursue long-term supply agreements, or qualify alternative suppliers to mitigate exposure. Importantly, regulatory considerations and payer negotiations will influence how any incremental costs are ultimately distributed across payers, providers, and patients, so cross-functional mitigation strategies that include evidence generation and pricing models are essential to preserve patient access.

Deep segmentation insights describing how therapy class, distribution pathways, delivery modes, end-use settings, and patient age groups define strategic priorities and operational trade-offs

A segmented view of the alpha-1 antitrypsin deficiency therapeutic landscape highlights distinct commercial and clinical vectors that stakeholders must address to optimize development and deployment. Considering therapy class, augmentation therapy and plasma infusion continue to form the backbone of current management for many patients, with operational emphasis on plasma collection networks, cold-chain logistics, and infusion infrastructure. Gene therapy occupies a different risk-reward profile; within this class, AAV vector approaches are favored for in vivo gene delivery targeting the liver or lungs, whereas lentiviral vector strategies are typically explored in ex vivo hematopoietic paradigms or for certain systemic delivery goals. Each vector type carries unique manufacturing, immunogenicity, and regulatory considerations that shape clinical trial design and long-term safety monitoring.

Distribution channel dynamics exert material influence over patient access and adherence. Hospital pharmacies remain critical for complex, administration-intensive therapies and for initial gene therapy dosing, while online pharmacies are emerging as convenient conduits for chronic treatments and patient home delivery programs. Retail pharmacies provide neighborhood-level access and often support continuity of care for maintenance regimens. Delivery mode selection further segments patient experience: inhalation therapies offer targeted pulmonary deposition and potentially greater convenience for ambulatory patients, while intravenous delivery supports systemic exposure and controlled dosing in clinical settings. End-user distinctions matter as well; homecare models enable patients to receive chronic infusions outside institutional settings, hospitals serve as centers for acute management and complex procedures, and specialty clinics concentrate expertise for gene therapy administration and long-term monitoring. Finally, patient age group creates clinical variability that influences therapeutic selection, dosing strategies, and safety surveillance: pediatric populations require pediatric-specific formulations and developmental safety data, adults typically represent the largest treated cohort, and geriatrics bring comorbidity and polypharmacy considerations that affect tolerability and outcomes.

How distinct regional regulatory environments, clinical infrastructure, and supply chain capabilities shape development pathways and patient access across global markets

Regional dynamics materially influence clinical development, reimbursement strategy, and supply chain resilience for alpha-1 antitrypsin deficiency programs. In the Americas, concentrated research activity and extensive clinical trial infrastructure, alongside established plasma collection systems, create an environment conducive to advanced therapeutic development. Regulatory pathways remain a central consideration, with agencies requiring robust safety and long-term follow-up data that inform trial endpoints and post-approval obligations. Commercial stakeholders in this region must also navigate payer expectations and complex hospital procurement processes to ensure therapy uptake.

Europe, the Middle East & Africa present a heterogeneous regulatory and access landscape where centralized and national-level frameworks intersect. Several European markets provide strong orphan drug incentives and expedited review mechanisms, yet access can vary substantially by country due to differing reimbursement thresholds and health technology assessment requirements. In parts of the Middle East and Africa, constrained plasma infrastructure and limited specialty care networks can complicate implementation of advanced therapies, underscoring the importance of targeted capacity-building efforts.

Asia-Pacific is characterized by rapid growth in clinical research activity, increasing local manufacturing capabilities, and evolving regulatory harmonization efforts that aim to accelerate clinical development timelines. Several countries in this region are investing in biomanufacturing and vector production capacity, which can support regional supply diversification. However, patient access and pricing dynamics differ across markets, requiring nuanced commercialization strategies that reflect local payer systems, distribution ecosystems, and medical practice patterns. Across all regions, cross-border supply chains, tariff exposure, and logistics contingencies remain central to ensuring consistent product availability and sustained patient care.

Insights into how strategic partnerships, manufacturing investments, and evidence-generation programs among industry players are accelerating clinical translation and commercialization

Company- and ecosystem-level behaviors are shaping the pace at which innovative AATD therapies move from concept to clinic and ultimately into routine care. A diverse mix of small biotech innovators, established plasma therapeutics firms, contract development and manufacturing organizations, and specialty pharmacy networks contribute complementary capabilities across discovery, vector production, and patient support. Strategic alliances and licensing agreements are increasingly common as developers seek to combine scientific expertise with scale manufacturing competence and established distribution networks.

Commercial players are prioritizing capability investments in vector manufacturing, cold-chain logistics, and patient support services to address the operational complexities of both gene therapy and plasma-derived products. Contract manufacturers that can demonstrate consistent yields and regulatory-compliant quality systems become strategic partners for sponsors aiming to derisk pivotal programs. Meanwhile, specialty pharmacies and home infusion providers are enhancing clinical support and monitoring programs to optimize adherence and safety. On the business side, companies are also focusing on evidence generation strategies that align clinical outcomes with payer requirements, emphasizing real-world effectiveness, quality-of-life measures, and long-term safety data to support coverage and reimbursement discussions. Collectively, these company-level choices underscore a shift toward integrated, cross-functional approaches that blend clinical excellence with commercial pragmatism.

Practical and prioritized strategic steps for sponsors and partners to strengthen supply chains, evidence generation, and patient-centric commercialization for AATD therapies

To navigate the complex and rapidly evolving AATD ecosystem, industry leaders should prioritize a set of actionable strategies that balance near-term operational resilience with long-term innovation. First, diversify supply chains for plasma-derived inputs and vector manufacturing by qualifying multiple suppliers across geographies and by investing in domestic manufacturing capacity where feasible to mitigate tariff and logistics exposure. Second, accelerate clinical evidence generation that addresses payer concerns by incorporating robust real-world data collection and patient-reported outcomes into trial designs and post-approval registries, thereby strengthening reimbursement dialogues.

Third, align product development with delivery and distribution realities by designing formulations and administration pathways that suit hospital-based initiation, homecare continuation, or inhaled outpatient maintenance as appropriate. Fourth, build cross-sector partnerships with contract manufacturing organizations, specialty pharmacies, and clinical centers of excellence to ensure scalable production and high-quality patient support. Fifth, engage proactively with regulators and health technology assessment bodies to define acceptable endpoints and risk management plans, especially for novel gene therapies. Finally, invest in patient-centric programs that reduce adherence barriers and support long-term monitoring, particularly for pediatric and geriatric populations where safety and tolerability considerations differ. These recommendations, implemented in concert, will help organizations preserve access, limit operational disruption, and enhance the clinical value proposition of new therapies.

A transparent description of the mixed-methods research approach combining primary interviews, literature synthesis, and operational vendor assessment to ensure robust and actionable conclusions

The research underpinning this executive summary integrates multiple lines of inquiry to produce a rigorous and actionable synthesis of the alpha-1 antitrypsin deficiency treatment landscape. Primary research included structured interviews with clinical investigators, specialty pharmacists, manufacturing leaders, and payer representatives to capture frontline perspectives on clinical practice, operational constraints, and coverage considerations. Secondary research encompassed a comprehensive review of peer-reviewed literature, clinical trial registries, regulatory guidance documents, and public company disclosures to map scientific progress, trial activity, and regulatory expectations.

Supply chain and manufacturing insights were derived from vendor assessments and publicly available manufacturing capacity reports, while distribution-channel analysis incorporated data on pharmacy service offerings and homecare program models. Where appropriate, triangulation was applied across primary and secondary sources to validate trends and to identify divergent signals. Analytical rigor was maintained through cross-functional review and quality assurance checks to ensure that conclusions reflect consistent evidence. Limitations of the methodology include variability in publicly reported timelines for clinical programs and the inherent uncertainty associated with evolving policy environments, which we mitigated by emphasizing risk-adjusted scenarios and operational contingencies rather than precise numerical projections.

A forward-looking synthesis emphasizing coordinated strategies across development, manufacturing, and payer engagement to translate scientific progress into sustained patient access

The convergence of biologic therapies, gene-based innovation, and evolving distribution models presents a pivotal moment for the management of alpha-1 antitrypsin deficiency. Scientific advances create tangible opportunities to move beyond symptomatic control toward more durable therapeutic outcomes, yet realizing that potential requires coherent strategies that span clinical development, manufacturing resilience, and payer engagement. By aligning vector platform choices with delivery modalities and by integrating robust real-world evidence into regulatory and reimbursement conversations, stakeholders can reduce barriers to adoption and improve patient outcomes.

Moving forward, collaboration among developers, contract manufacturers, specialty care providers, and payers will be essential to translate scientific progress into broad patient benefit. Operational preparedness-particularly with respect to supply chain diversification and pricing strategies-will determine which therapies achieve sustainable access. Ultimately, a patient-centered approach that prioritizes safety, long-term monitoring, and equitable access will not only advance clinical care but also create durable commercial pathways for innovative treatments in this therapeutic area.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emerging gene editing therapies leveraging CRISPR technology for durable alpha 1 antitrypsin expression in the lung
  • 5.2. Clinical advancement of recombinant AAT inhalation formulations to improve patient compliance and outcomes
  • 5.3. Integration of telemedicine platforms for real-time monitoring and personalized management of AAT deficiency
  • 5.4. Expansion of newborn screening initiatives to facilitate early diagnosis and treatment of alpha 1 antitrypsin deficiency
  • 5.5. Market entry strategies for biosimilar AAT products in Europe amid evolving regulatory and pricing pressures
  • 5.6. Innovative nanoparticle-based delivery systems enhancing pulmonary targeting of alpha 1 antitrypsin therapies
  • 5.7. Adoption of long-acting AAT formulations reducing infusion frequency and improving adherence in chronic therapy
  • 5.8. Growing patient registry collaborations generating real-world evidence to support health technology assessments for AAT treatments

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Alpha 1 Antitrypsin Deficiency Treatment Market, by Therapy Class

  • 8.1. Augmentation Therapy
  • 8.2. Gene Therapy
    • 8.2.1. AAV Vector
    • 8.2.2. Lentiviral Vector
  • 8.3. Plasma Infusion

9. Alpha 1 Antitrypsin Deficiency Treatment Market, by Distribution Channel

  • 9.1. Hospital Pharmacy
  • 9.2. Online Pharmacy
  • 9.3. Retail Pharmacy

10. Alpha 1 Antitrypsin Deficiency Treatment Market, by Delivery Mode

  • 10.1. Inhalation
  • 10.2. Intravenous

11. Alpha 1 Antitrypsin Deficiency Treatment Market, by End User

  • 11.1. Homecare
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Alpha 1 Antitrypsin Deficiency Treatment Market, by Patient Age Group

  • 12.1. Adults
  • 12.2. Geriatrics
  • 12.3. Pediatrics

13. Alpha 1 Antitrypsin Deficiency Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Alpha 1 Antitrypsin Deficiency Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Alpha 1 Antitrypsin Deficiency Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Grifols S.A.
    • 16.3.2. CSL Behring GmbH
    • 16.3.3. Takeda Pharmaceutical Company Limited
    • 16.3.4. Kamada Pharmaceuticals
    • 16.3.5. Vertex Pharmaceuticals

LIST OF FIGURES

  • FIGURE 1. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AUGMENTATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AUGMENTATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AUGMENTATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AUGMENTATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AUGMENTATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AUGMENTATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AAV VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AAV VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AAV VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AAV VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AAV VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AAV VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PLASMA INFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PLASMA INFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PLASMA INFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PLASMA INFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PLASMA INFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PLASMA INFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOMECARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOMECARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GERIATRICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GERIATRICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GERIATRICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PEDIATRICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PEDIATRICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 125. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 127. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 132. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 138. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 140. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 146. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 148. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 150. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 152. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 188. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 190. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 192. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 194. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 202. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 203. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 204. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 205. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 208. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 209. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 232. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 233. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 234. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 235. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 238. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 239. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 246. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 247. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 248. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 249. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 252. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 253. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 274. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 275. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY T